Zynga Launches Harry Potter: Puzzles & Spells Worldwide
23.9.2020 13:00:00 EEST | Business Wire | Press release
Today, Zynga Inc. (Nasdaq: ZNGA), a global leader in interactive entertainment, announced that its magical Match-3 mobile game Harry Potter: Puzzles & Spells has officially launched and begun rolling out to territories worldwide. Officially licensed from Warner Bros. Games and published under the Portkey Games label, the game is available for free download on Android and iOS devices, as well as on Amazon Kindle and Facebook.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200923005144/en/
Zynga Launches Harry Potter: Puzzles & Spells Worldwide (Photo: Business Wire)
“When the Harry Potter series first came to theatres, it was one of those rare moments when everyone was reading the same book, talking about the same film and coming together around a shared experience,” said Yaron Leyvand, Senior Vice President of Games at Zynga. “Harry Potter: Puzzles & Spells honours fans' connection to the series with a mobile game infused with the standout moments and delightful Wizarding World flourishes that have captivated a global following. The feedback from soft-launch has been outstanding, and we can’t wait for fans around the world to play.”
“Mobile games have never been more popular or more important to people than they are right now. People are playing games for entertainment, relaxation, and as an accessible source of comfort and connection,” said Bernard Kim, President of Publishing at Zynga. “With Harry Potter: Puzzles & Spells, fans will immerse themselves in the magic, puzzles, and wonder of the series and create Clubs to collaborate and connect with others fans of Wizarding World.”
In Harry Potter: Puzzles & Spells, players enter a Match-3 adventure brimming with the spells, humour, colour and characters of the Harry Potter series. Featuring the soundtrack and voiceover recordings from the original Harry Potter films, fans follow an authentic, mobile retelling of Harry’s journey through the Wizarding World. Earning spells and special boosts as they advance, players solve Match-3 puzzles populated with hopping Chocolate Frogs, fluttering Winged Keys, battling wizard chess pieces, and other unexpected obstacles and objects. Between colourful puzzles, players will be treated to iconic moments from the narrative, such as Harry’s journey on the Hogwarts Express, Hagrid’s magical creatures and Hermione casting the Wingardium Leviosa spell.
Building their magical aptitude, players earn spells, powerups, and experience points as they progress through the game to level up their skills and in-game personas. Players can also earn powerful rewards by completing Daily Events that reference a multitude of moments from the Harry Potter series. In the spirit of the camaraderie and friendly competition of Hogwarts, players can join or form clubs with other fans to socialise, collaborate on puzzle strategies, share lives and vie for prizes in exclusive Club Events.
For the next seven days, players who download the game for their Android or iOS device will instantly receive the Welcome Bundle, containing in-game gold, extra lives and special Quidditch Goggles to customize their avatars.
Harry Potter: Puzzles & Spells is playable for iOS and Android devices worldwide, as well as on Amazon Kindle and Facebook. For more details, visit the game’s website at www.harrypotterpuzzlesandspells.com. For more information and to connect with other fans, follow us on Facebook, Instagram and Twitter.
For supporting still and video assets, visit: http://bit.ly/HPPuzzlesSpells_WWL
About Zynga
Zynga is a global leader in interactive entertainment with a mission to connect the world through games. To date, more than one billion people have played Zynga’s franchises including CSR Racing TM, Empires & Puzzles TM, Merge Dragons! TM, Merge Magic! TM, Toon Blast™, Toy Blast™, Words With Friends TM and Zynga Poker TM. Zynga’s games are available in more than 150 countries and are playable across social platforms and mobile devices worldwide. Founded in 2007, the company is headquartered in San Francisco with locations in the U.S., Canada, U.K., Ireland, India, Turkey and Finland. For more information, visit www.zynga.com or follow Zynga on Twitter, Instagram, Facebook or the Zynga blog.
About Warner Bros. Games
Warner Bros. Games, a division of Warner Bros. Home Entertainment, Inc., is a premier worldwide publisher, developer, licensor and distributor of entertainment content for the interactive space across all platforms, including console, handheld, mobile and PC-based gaming for both internal and third-party game titles. Additional information about Warner Bros. Games can be found at https://www.wbgames.com/.
About Portkey Games
Portkey Games, from Warner Bros. Games, is the games label dedicated to creating new Wizarding World mobile and videogame experiences that place the player at the center of their own adventure, inspired by J.K. Rowling’s original stories. Portkey Games offers players the opportunity to make their own narrative choices and engage with the Wizarding World setting to create new and unique experiences. The label was created to bring gamers and fans new gaming experiences that allow them to delve into the magic of the Wizarding World in immersive ways where they can define their own Wizarding World story.
Forward Looking Statements
This press release contains forward-looking statements relating to, among other things, the name, gameplay details, game features, and a limited-time promotion in Harry Potter: Puzzles & Spells. Forward-looking statements often include words such as “outlook,” “projected,” “planned,” “intends,” “will,” “anticipate,” “believe,” “target,” “expect,” and statements in the future tense are generally forward-looking. The achievement or success of the matters covered by such forward-looking statements involves significant risks, uncertainties and assumptions. Undue reliance should not be placed on such forward-looking statements, which are based on information available to us on the date hereof. We assume no obligation to update such statements. More information about these risks, uncertainties, and assumptions is or will be described in greater detail in our public filings with the Securities and Exchange Commission (the “SEC”), copies of which may be obtained by visiting our Investor Relations website at http://investor.zynga.com or the SEC’s website at www.sec.gov.
WIZARDING WORLD, HARRY POTTER Publishing Rights © J.K. Rowling. HARRY POTTER: PUZZLES & SPELLS, PORTKEY GAMES, WIZARDING WORLD and HARRY POTTER characters, names and related indicia © and ™ Warner Bros. Entertainment Inc. ™ Zynga Inc. All Rights Reserved.
WB SHIELD: ™ & © Warner Bros. Entertainment Inc. (s20)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200923005144/en/
Contact information
Dana Whitney
dwhitney@zynga.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom